Agios Pharmaceuticals Inc. (NASDAQ:AGIO) dropped 2.3% on Tuesday . The company traded as low as $36.75 and last traded at $36.90, with a volume of 339,728 shares changing hands. The stock had previously closed at $37.76.

A number of research analysts recently issued reports on AGIO shares. JPMorgan Chase & Co. upgraded shares of Agios Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $50.00 to $62.00 in a report on Monday, June 13th. Credit Suisse Group AG reiterated a “buy” rating on shares of Agios Pharmaceuticals in a report on Tuesday, July 12th. Canaccord Genuity upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price objective for the company from $50.00 to $90.00 in a report on Monday, June 13th. BTIG Research started coverage on shares of Agios Pharmaceuticals in a report on Friday, August 19th. They issued a “neutral” rating for the company. Finally, Goldman Sachs Group Inc. reiterated a “neutral” rating and issued a $46.00 price objective on shares of Agios Pharmaceuticals in a report on Wednesday, August 10th. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $63.44.

The firm’s 50 day moving average is $41.74 and its 200-day moving average is $44.73. The company’s market capitalization is $1.39 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.47) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by $0.99. During the same period last year, the firm earned ($0.85) earnings per share. The firm earned $6.98 million during the quarter, compared to the consensus estimate of $39.62 million. The company’s quarterly revenue was down 47.2% compared to the same quarter last year. Equities research analysts expect that Agios Pharmaceuticals Inc. will post ($5.02) earnings per share for the current fiscal year.

In other Agios Pharmaceuticals news, Director Lewis Clayton Jr. Cantley sold 2,504 shares of the company’s stock in a transaction that occurred on Tuesday, June 28th. The stock was sold at an average price of $41.88, for a total value of $104,867.52. Following the completion of the sale, the director now owns 125,921 shares of the company’s stock, valued at $5,273,571.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Scott Biller sold 27,500 shares of the company’s stock in a transaction that occurred on Wednesday, June 8th. The stock was sold at an average price of $65.00, for a total value of $1,787,500.00. Following the completion of the sale, the insider now directly owns 81,376 shares of the company’s stock, valued at approximately $5,289,440. The disclosure for this sale can be found here.

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.